Advertisement
Screener

CDT EQUITY INC. (CDT) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

CDT EQUITY INC. Research and Development Expense

CDT EQUITY INC. (CDT) reported Research and Development Expense of $302.00 thousand for the 3-month period ending 2026-06-30, per its S-1 filed 2026-09-08.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-08

  • CDT EQUITY INC. research and development expense for the quarter ending 2026-06-30 was $302.00K, a 83.76% decline year-over-year.
  • CDT EQUITY INC. research and development expense for the quarter ending 2026-03-31 was $778.00K, a 15.07% decline year-over-year.
  • CDT EQUITY INC. research and development expense for the quarter ending 2025-12-31 was $746.00K, a 465.15% increase year-over-year.
  • CDT EQUITY INC. research and development expense for the quarter ending 2025-09-30 was $1.53M, a 50.47% decline year-over-year.
  • CDT EQUITY INC. research and development expense for fiscal 2023 was $90.00K, a 143.24% increase from fiscal 2022.
  • CDT EQUITY INC. research and development expense for fiscal 2022 was $37.00K.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 9 monthResearch and Development Expense 12 month
2026-06-30$302.00K
S-1 · filed 2026-09-08
$1.08M
S-1 · filed 2026-09-08
$1.83M
derived: sum of 3 quarters · filed 2026-09-08
$3.36M
derived: sum of 4 quarters · filed 2026-09-08
2026-03-31$778.00K
10-Q · filed 2026-07-15
$1.52M
derived: sum of 2 quarters · filed 2026-09-08
$3.06M
derived: sum of 3 quarters · filed 2026-09-08
$4.92M
derived: sum of 4 quarters · filed 2026-09-08
2025-12-31$746.00K
derived: S-1 12 month − 10-Q 9 month · filed 2026-09-08
$2.28M
derived: sum of 2 quarters · filed 2026-09-08
$4.14M
derived: sum of 3 quarters · filed 2026-09-08
$5.05M
S-1 · filed 2026-09-08
2025-09-30$1.53M
10-Q · filed 2025-11-13
$3.39M
derived: sum of 2 quarters · filed 2026-09-08
$4.31M
10-Q · filed 2025-11-13
$4.44M
derived: sum of 4 quarters · filed 2026-09-08
2025-06-30$1.86M
S-1 · filed 2026-09-08
$2.78M
S-1 · filed 2026-09-08
$2.91M
derived: sum of 3 quarters · filed 2026-09-08
$6.00M
derived: sum of 4 quarters · filed 2026-09-08
2025-03-31$916.00K
10-Q · filed 2026-07-15
$1.31M
10-Q · filed 2025-05-15
$1.05M
derived: sum of 2 quarters · filed 2026-09-08
$4.14M
derived: sum of 3 quarters · filed 2026-09-08
$4.17M
derived: sum of 4 quarters · filed 2026-09-08
2024-12-31$132.00K
derived: S-1 12 month − 10-Q 9 month · filed 2026-09-08
$3.23M
derived: sum of 2 quarters · filed 2026-09-08
$3.25M
derived: sum of 3 quarters · filed 2026-09-08
$3.38M
S-1 · filed 2026-09-08
2024-09-30$3.09M
10-Q · filed 2025-11-13
$3.12M
derived: sum of 2 quarters · filed 2025-11-13
$3.25M
10-Q · filed 2025-11-13
2024-06-30$25.00K
10-Q · filed 2025-08-14
$153.00K
10-Q · filed 2025-08-14
2024-03-31$128.00K
10-Q/A · filed 2025-08-14
2023-12-31$90.00K
10-K · filed 2025-03-28
2022-12-31-$1.00K
derived: 10-K 12 month − 10-Q/A 9 month · filed 2024-04-16
$37.00K
derived: sum of 2 quarters · filed 2024-04-16
$37.00K
10-K · filed 2024-04-16
2022-09-30$38.00K
10-Q/A · filed 2023-11-21
$38.00K
10-Q/A · filed 2023-11-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aditxt, Inc. (ADTX)United States$0.000B
Rafael Holdings, Inc. (RFL)United States$0.000B-0.00
Protagenic Therapeutics, Inc.\new (PTIX)United States$0.001B
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
Nexentis Technologies Inc. (NXTS)$0.002B
ORAGENICS INC (OGEN)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B